{
    "clinical_study": {
        "@rank": "139699", 
        "acronym": "INNOVATE", 
        "arm_group": {
            "arm_group_label": "chemotherapy and erlotinib", 
            "arm_group_type": "Experimental", 
            "description": "Intercalated combination of chemotherapy and erlotinib in 1st line setting for patients with advanced stage non-small-cell lung cancer with low abundant activating EGFR mutation"
        }, 
        "brief_summary": {
            "textblock": "This is a single arm phase II clinical trial, which aims to evaluate the effectiveness of\n      intercalated combination of doublet chemotherapy of paclitaxel plus carboplatin and\n      erlotinib on patients with advanced stage non-small-cell lung cancer with low abundant\n      activating EGFR mutation."
        }, 
        "brief_title": "Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small-cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Primary therapy stage:\n\n      Paclitaxel Patients receive six cycles of Paclitaxel (175 mg/m\u00b2 on days 1 of a 4 week cycle,\n      intravenously) plus carboplatin (AUC=5, intravenously on day 1 of a 4 week cycle,\n      intravenously) with sequential erlotinib (150 mg/day) on days 8-21 of each cycle.\n\n      Maintenance therapy stage:\n\n      Patients, who complete 6 cycles of therapy without progression or intolerable toxicity,\n      receive erlotinib (150 mg/day) as maintenance therapy until progression, intolerable\n      toxicity or death."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:Patients with histologically documented, locally advanced or recurrent\n        (stage IIIb and not amenable to combined modality treatment) or metastatic (stage IV)\n        non-small cell lung cancer.\n\n        Low abundant activating EGFR mutation: EGFR exon 19 deletion or exon 21 L858R, which are\n        positive by real-time PCR methods and negative by standard sequencing methods.\n\n        Uncommon EGFR mutations are included excluding exon 20 mutations. ECOG performance status\n        of \u2264 2. Patients can administer first line setting of platinum based chemotherapy.\n        Patients must have measurable disease according to the RECIST (version 1.1) criteria.\n\n          -  Life expectancy of at least 12 weeks.\n\n          -  Age \u2265 18 years.\n\n          -  Written (signed) informed Consent to participate in the study.\n\n          -  Adequate organ function as defined by the following criteria:\n\n        Liver function: SGOT (AST) and SGPT (ALT) \u2264 2.5 X ULN in the absence of liver metastases\n        or up to 5 X ULN in case of liver metastases. Total bilirubin \u2264 1.5ULN.\n\n        Bone marrow function: Granulocyte count \u2265 1,500/mm3 and platelet count \u2265100,000/mm3 and\n        hemoglobin \u226590g/dl.\n\n        Renal function: serum creatinine \u2264 1.5 ULN or creatinine clearance \u2265 60 ml/min. (based on\n        modified Cockcroft-Gault formula).\n\n          -  For all females of childbearing potential a negative serum/urine pregnancy test must\n             be obtained within 48 hours before enrollment. Postmenopausal women must have been\n             amenorrhoeic for at least 12 months to be considered of non-childbearing potential.\n\n        Exclusion Criteria:Patients with prior chemotherapy or systemic anti-cancer therapy\n        including target therapy targeting HER family members (such as erlotinib, gefitinib,\n        cetuximab, trastuzumab, etc). Previous adjuvant or neo-adjuvant treatment for\n        non-metastatic disease is permitted if completed \u2265 6 months before the enrollments.\n\n          -  Patients with history of any other malignancies within 5 years (except for adequately\n             treated carcinoma in situ of the cervix or basal or squamous cell skin cancer).\n\n          -  Patients who have brain metastasis or spinal cord compression. It is permitted if the\n             patient has been treated with surgery and/or radiation with evidence of stable\n             disease for at least 4 weeks.\n\n          -  Patients who are at risk (in the investigator's opinion) of transmitting human\n             immunodeficiency virus (HIV) through blood or other body fluids.\n\n          -  Nursing or lactating women.\n\n          -  Sexually active males and females (of childbearing potential) unwilling to practice\n             contraception during the study.\n\n          -  Unwilling to write informed consent to participate in the study.\n\n          -  Patients who is unwilling to accept the follow-up."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02095782", 
            "org_study_id": "CTONG1307"
        }, 
        "intervention": {
            "arm_group_label": "chemotherapy and erlotinib", 
            "description": "Primary therapy stage:\nPaclitaxel Patients receive six cycles of Paclitaxel (175 mg/m\u00b2 on days 1 of a 4 week cycle, intravenously) plus carboplatin (AUC=5, intravenously on day 1 of a 4 week cycle, intravenously) with sequential erlotinib (150 mg/day) on days 8-21 of each cycle.\nMaintenance therapy stage:\nPatients, who complete 6 cycles of therapy without progression or intolerable toxicity, receive erlotinib (150 mg/day) as maintenance therapy until progression, intolerable toxicity or death.", 
            "intervention_name": "Intercalated combination of chemotherapy and erlotinib", 
            "intervention_type": "Drug", 
            "other_name": "paclitaxel plus carboplatin and targeted therapy erlotinib"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Carboplatin", 
                "Paclitaxel", 
                "Erlotinib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "non-small cell lung cancer", 
            "erlotinib", 
            "chemotherapy"
        ], 
        "lastchanged_date": "March 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510080"
                }, 
                "name": "Guangdong General Hospital & Guangdong Academy of Medical Sciences"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Intercalated Combination of Chemotherapy and Erlotinib in 1st Line Setting for Patients Advanced Stage Non-small-cell Lung Cancer With Low Abundant Activating EGFR Mutation(INNOVATE)", 
        "overall_official": [
            {
                "affiliation": "Guangdong General Hospital (GGH)& Guangdong Academy of Medical Sciences", 
                "last_name": "Yi-Long Wu", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Guangdong General Hospital & Guangdong Academy of Medical Sciences", 
                "last_name": "Zhen Wang, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "From start of anti-cancer therapy untill progression or death", 
            "measure": "Progression free survival defined by imagery methods", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02095782"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Guangdong Association of Clinical Trials", 
            "investigator_full_name": "Yi-Long Wu", 
            "investigator_title": "Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "From start of anti-cancer therapy till progression of death", 
            "measure": "Toxicities   related to anti-cancer therapy", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks"
        }, 
        "source": "Guangdong Association of Clinical Trials", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Guangdong Association of Clinical Trials", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}